Assertio Therapeutics Net Income
| ASRT Stock | USD 11.99 0.25 2.04% |
As of the 4th of February, Assertio Therapeutics shows the Mean Deviation of 2.66, downside deviation of 3.38, and Risk Adjusted Performance of 0.0229. Assertio Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Assertio Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.165 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -19.4 M | -20.4 M | |
| Net Income Applicable To Common Shares | 98.7 M | 103.6 M | |
| Net Loss | -19.4 M | -20.4 M | |
| Net Loss | (3.06) | (3.21) | |
| Net Income Per E B T | 0.90 | 1.24 |
Assertio | Net Income | Build AI portfolio with Assertio Stock |
The evolution of Net Income for Assertio Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Assertio Therapeutics compares to historical norms and industry peers.
Latest Assertio Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Assertio Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Assertio Therapeutics financial statement analysis. It represents the amount of money remaining after all of Assertio Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Assertio Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Assertio Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (21.58 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Assertio Net Income Regression Statistics
| Arithmetic Mean | (32,050,997) | |
| Geometric Mean | 36,558,079 | |
| Coefficient Of Variation | (352.79) | |
| Mean Deviation | 77,157,884 | |
| Median | (20,394,045) | |
| Standard Deviation | 113,073,590 | |
| Sample Variance | 12785.6T | |
| Range | 463.7M | |
| R-Value | (0.27) | |
| Mean Square Error | 12636.3T | |
| R-Squared | 0.07 | |
| Significance | 0.29 | |
| Slope | (6,068,627) | |
| Total Sum of Squares | 204570.2T |
Assertio Net Income History
Other Fundumenentals of Assertio Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Assertio Therapeutics Net Income component correlations
Assertio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Assertio Therapeutics is extremely important. It helps to project a fair market value of Assertio Stock properly, considering its historical fundamentals such as Net Income. Since Assertio Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Assertio Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Assertio Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Pharmaceuticals market expansion? Will Assertio introduce new products? Factors like these will boost the valuation of Assertio Therapeutics. If investors know Assertio will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Assertio Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.19) | Earnings Share (4.50) | Revenue Per Share | Quarterly Revenue Growth 0.694 | Return On Assets |
Understanding Assertio Therapeutics requires distinguishing between market price and book value, where the latter reflects Assertio's accounting equity. The concept of intrinsic value - what Assertio Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Assertio Therapeutics' price substantially above or below its fundamental value.
Understanding that Assertio Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Assertio Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Assertio Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Assertio Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Assertio Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Assertio Therapeutics.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Assertio Therapeutics on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Assertio Therapeutics or generate 0.0% return on investment in Assertio Therapeutics over 90 days. Assertio Therapeutics is related to or competes with INC Research, Nutriband, XBiotech, Fortress Biotech, Acrivon Therapeutics, Tscan Therapeutics, and Pulmonx Corp. Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and... More
Assertio Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Assertio Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Assertio Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.38 | |||
| Information Ratio | 0.0064 | |||
| Maximum Drawdown | 24.64 | |||
| Value At Risk | (5.00) | |||
| Potential Upside | 6.07 |
Assertio Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Assertio Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Assertio Therapeutics' standard deviation. In reality, there are many statistical measures that can use Assertio Therapeutics historical prices to predict the future Assertio Therapeutics' volatility.| Risk Adjusted Performance | 0.0229 | |||
| Jensen Alpha | 0.0451 | |||
| Total Risk Alpha | (0.16) | |||
| Sortino Ratio | 0.0073 | |||
| Treynor Ratio | 0.1286 |
Assertio Therapeutics February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0229 | |||
| Market Risk Adjusted Performance | 0.1386 | |||
| Mean Deviation | 2.66 | |||
| Semi Deviation | 3.22 | |||
| Downside Deviation | 3.38 | |||
| Coefficient Of Variation | 4963.02 | |||
| Standard Deviation | 3.86 | |||
| Variance | 14.88 | |||
| Information Ratio | 0.0064 | |||
| Jensen Alpha | 0.0451 | |||
| Total Risk Alpha | (0.16) | |||
| Sortino Ratio | 0.0073 | |||
| Treynor Ratio | 0.1286 | |||
| Maximum Drawdown | 24.64 | |||
| Value At Risk | (5.00) | |||
| Potential Upside | 6.07 | |||
| Downside Variance | 11.43 | |||
| Semi Variance | 10.34 | |||
| Expected Short fall | (2.91) | |||
| Skewness | 1.09 | |||
| Kurtosis | 3.42 |
Assertio Therapeutics Backtested Returns
Currently, Assertio Therapeutics is somewhat reliable. Assertio Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0486, which signifies that the company had a 0.0486 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Assertio Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm Assertio Therapeutics' Downside Deviation of 3.38, mean deviation of 2.66, and Risk Adjusted Performance of 0.0229 to double-check if the risk estimate we provide is consistent with the expected return of 0.19%. Assertio Therapeutics has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.53, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Assertio Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Assertio Therapeutics is expected to be smaller as well. Assertio Therapeutics right now shows a risk of 3.93%. Please confirm Assertio Therapeutics value at risk, as well as the relationship between the kurtosis and market facilitation index , to decide if Assertio Therapeutics will be following its price patterns.
Auto-correlation | -0.06 |
Very weak reverse predictability
Assertio Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Assertio Therapeutics time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Assertio Therapeutics price movement. The serial correlation of -0.06 indicates that barely 6.0% of current Assertio Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.06 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 1.29 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Assertio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Assertio Therapeutics reported net income of (21.58 Million). This is 106.32% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 103.78% higher than that of the company.
Assertio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Assertio Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Assertio Therapeutics could also be used in its relative valuation, which is a method of valuing Assertio Therapeutics by comparing valuation metrics of similar companies.Assertio Therapeutics is currently under evaluation in net income category among its peers.
Assertio Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Assertio Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Assertio Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Assertio Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Assertio Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Assertio Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Assertio Therapeutics' value.| Shares | State Street Corp | 2025-06-30 | 366.9 K | Perritt Capital Management Inc. | 2025-06-30 | 360.3 K | Ubs Group Ag | 2025-06-30 | 334.2 K | Tsp Capital Management Group/llc | 2025-06-30 | 316.9 K | Citadel Advisors Llc | 2025-06-30 | 288.8 K | Amvescap Plc. | 2025-06-30 | 270.7 K | Northern Trust Corp | 2025-06-30 | 227.2 K | Bridgeway Capital Management, Llc | 2025-06-30 | 223.4 K | Empowered Funds, Llc | 2025-06-30 | 223.4 K | Nantahala Capital Management, Llc | 2025-06-30 | 8.8 M | Vanguard Group Inc | 2025-06-30 | 4.4 M |
Assertio Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0417 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 22.67 M | ||||
| Shares Outstanding | 6.42 M | ||||
| Shares Owned By Insiders | 2.49 % | ||||
| Shares Owned By Institutions | 28.47 % | ||||
| Number Of Shares Shorted | 271.83 K | ||||
| Price To Earning | 4.93 X | ||||
| Price To Book | 0.72 X | ||||
| Price To Sales | 0.56 X | ||||
| Revenue | 124.96 M | ||||
| Gross Profit | 89.93 M | ||||
| EBITDA | 5.15 M | ||||
| Net Income | (21.58 M) | ||||
| Cash And Equivalents | 52.26 M | ||||
| Cash Per Share | 1.09 X | ||||
| Total Debt | 40.27 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 1.00 X | ||||
| Book Value Per Share | 16.49 X | ||||
| Cash Flow From Operations | 26.41 M | ||||
| Short Ratio | 4.20 X | ||||
| Earnings Per Share | (4.50) X | ||||
| Price To Earnings To Growth | 1.50 X | ||||
| Target Price | 37.44 | ||||
| Number Of Employees | 58 | ||||
| Beta | 0.73 | ||||
| Market Capitalization | 76.94 M | ||||
| Total Asset | 284.73 M | ||||
| Retained Earnings | (673.12 M) | ||||
| Working Capital | 87.86 M | ||||
| Current Asset | 5.15 M | ||||
| Current Liabilities | 492.4 K | ||||
| Net Asset | 284.73 M |
About Assertio Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Assertio Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Assertio Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Assertio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.